



27-FEB-1998-0457

McNEIL CO
FORT

Individual Safety Report



3037714-4-00

DA on 11/16/93

FDA use only

A. Patient information

1. Patient identifier Case 2 In confidence	2. Age at time of event: 74 yrs or Date of birth:	3. Sex (X) female () male	4. Weight unk lbs or kgs
--	--	----------------------------------	-----------------------------------

B. Adverse event or product problem

1. X Adverse event and/or Product problem (e.g., defects/malfunctions)	
2. Outcomes attributed to adverse event (check all that apply)	() disability () congenital anomaly () required intervention to prevent permanent impairment/damage () other:
(X) death 5/1/93 (mo/day/yr)	
() life-threatening	
(X) hospitalization - initial or prolonged	
3. Date of event (mo/day/yr) 4/29/93	4. Date of this report (mo/day/yr) 02/11/98

5. Describe event or problem

Reports of 19 cases compiled by attorney & sent to FDA; Agency forwarded these reports to McNeil upon request to Docket No. 77N-094W, Ref. 94, Vol. 6 of 7. Of the 19 cases, 11 were previously submitted to FDA by McNeil (Mfr. # 0158783A, 0171537A, 0284020A, 0325998A, 0374114A, 0495613A, 0505064A, 0505223A, 0505252A, 0599479A, 0673820A). Case document #2 of a 74yo female w/prior heavy ethyl alcohol hx was admitted to hosp on 4/29/93 w/2d hx of N/V & generalized ill feeling. Pt had been consuming a lot of analgesics including DARVOCET® and acetaminophen (up to 10-12 5gr tabs/day) (OVERDOSE) for pain. In hosp, pt noted to have elevated LFTs, metabolic acidosis & HEPATORENAL SYNDROME w/multiple organ failure. Pt died (DEATH) on 5/1/93. Autopsy final dx: massive central lobular hepatocellular necrosis (LIVER NECROSIS) c/w toxin induced hepatocellular damage, swelling & pallor of kidney w/acute tubular necrosis (KIDNEY TUBULAR NECROSIS), generalized JAUNDICE, moderate pulmonary edema (LUNG EDEMA), moderate abdominal ASCITES & ischemia of proximal small bowel.

6. Relevant tests/laboratory data, including dates

4/29/93: LDH=10,776 U/L, GOT=10,584 U/L, GPT=4308 U/L, GAMMA GT=476 U/L, CPK=374 U/L, BUN=30mg/dL, Scr.=4.4mg/dL, UA=10.8 mg/dL, WBC=22,300, Hct=38.2, PLT=220,000, PT=30.5, PTT=55.5, pH=6.95, PCO2=13, PO2=86, HCO3=3.1, (See Sect B7)

7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

hx of recent surgery on left toes, hypertension, past hx of low thyroid, significant sciatica & abnormal LFTs, gravida 5, para 4, AB 1; post-menopausal; drinks 1-2 cups of caffeine/day & ethyl alcohol use has been heavy in the past, but she reportedly has been off alcohol last 4-6 wks (Sect B6 cont'd): % saturation=92.9%, acetaminophen (See Sect C10)

1. Name (give labeled strength & mfr/labeler, if known)

#1 unspecified acetaminophen product
#2 DARVOCET®

2. Dose, frequency & route used

#1 up to 10-12 5gr tabs/day

#2 unknown dose, q4h prn, po

3. Therapy dates (if unknown, give duration) from/to (or best estimate)

#1 unknown dates or duration

#2 unknown dates or duration

4. Diagnosis for use (indication)

#1 post-surgical pain

#2 post-surgical pain

5. Event abated after use stopped or dose reduced

#1 () Yes () No (X) N/A

#2 () Yes () No (X) N/A

6. Lot # (if known)

#1 Unknown

#2 unknown

7. Exp. date (if known)

#1 Unknown

#2 unknown

8. Event reappeared after reintroduction

#1 () Yes () No (X) N/A

#2 () Yes () No (X) N/A

9. NDC # - for product problems only (if known)

10. Concomitant medical products and therapy dates (exclude treatment of event) PROCARDIA® XL (since 2/15/93) and DYZIDE® (since 2/15/93) (Sect B7 cont'd): level=23ug/ml; hepatitis A & B serologies were negative; chest X-ray showed congestion and edema 4/30/93: lactate was high at 149mg/dL

G. All manufacturers

1. Contact office - name/address (& mailing site for devices) McNeil Consumer Products Company Medical Affairs 7050 Camp Hill Road Ft. Washington, PA 19034	2. Phone number 215-233-7820
3. Report source (check all that apply) () foreign () study () literature () consumer () health professional () user facility () company representative () distributor (X) other: attorney	
4. Date received by manufacturer (mo/day/yr) 12/31/97	5. (A) NDA # 17-552 IND # PLA # pre-1938 () Yes OTC product (X) Yes
6. H IND, protocol #	
7. Type of report (check all that apply) () 5-day (X) 16-day () 10-day () periodic (X) Initial () follow-up #	
8. Mfr. report number 0932272A	
8. Adverse event term(s) OVERDOSE HEPATORENAL SYN DEATH JAUNDICE NECROSIS LIVER NECRO KIDNEY TU EDEMA LUNG ASCITES	

E. Initial reporter

1. Name, address & phone # [REDACTED] [REDACTED] [REDACTED] [REDACTED]	2. Health professional? () Yes (X) No	3. Occupation attorney	4. Initial reporter also sent report to FDA (X) Yes () No () Unk
--	---	---------------------------	---



Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.